BMS-backed Arsenal Bio pulls trigger on $220M series B, touting potential fleet of gene-edited cell therapies

BMS-backed Arsenal Bio pulls trigger on $220M series B, touting potential fleet of gene-edited cell therapies

Submitted by admin on September 6, 2022 - 10:39am
Source: 
Fierce Biotech
News Tags: 
Arsenal Bio
Bristol Myers Squibb
funding
cell therapy
Headline: 
BMS-backed Arsenal Bio pulls trigger on $220M series B, touting potential fleet of gene-edited cell therapies
snippet: 

Arsenal Bio is jumping headfirst into the cell therapy arena, and its latest fundraising haul, backed in part by Bristol Myers Squibb, is making a significant splash.

Do Not Allow Advertisers to Use My Personal information